UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 19, 2021

PROPHASE LABS, INC. (Exact name of Company as specified in its charter)		
Delaware (State or other jurisdiction of incorporation)	000-21617 (Commission File Number)	23-2577138 (I.R.S. Employer Identification No.)
711 Stewart Ave., Suite 200 Garden City, NY (Address of principal executive offices)		11530 (Zip Code)
Company's telephone number, including area cod	e: (215) 345-0919	
Check the appropriate box below if the Form 8 under any of the following provisions (see General		ultaneously satisfy the filing obligation of the Company
☐ Written communications pursuant to Rul	le 425 under the Securities A	act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-	12 under the Exchange Act	(17 CFR 240.14a-12)
☐ Pre-commencement communications pu	rsuant to Rule 14d-2(b) unde	er the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pu	rsuant to Rule 13e-4(c) unde	er the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) or	f the Exchange Act:	
Title of Each Class Common Stock, par value \$0.0005	Trading Symbol PRPH	Name of Each Exchange on Which Registered Nasdaq Capital Market
Indicate by check mark whether the registrant is (§230.405 of this chapter) or Rule 12b-2 of the Se		any as defined in Rule 405 of the Securities Act of 1933 34 (§240.12b-2 of this chapter).
		Emerging growth company □
If an emerging growth company, indicate by che complying with any new or revised financial accomplying with any new or revised financial accompany.	•	has elected not to use the extended transition period for bursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 19, 2021, the Compensation Committee of the Board of Directors of ProPhase Labs, Inc. (the "Company") approved a discretionary cash bonus payment to Monica Brady, the Company's Chief Financial Officer, in the amount of \$50,000, in recognition of her contributions to the Company for fiscal year 2021.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ProPhase Labs, Inc.

By:/s/Monica Brady

Monica Brady Chief Financial Officer

Date: January 4, 2022